Abstract
Ž y1 . ent rate constant s ; mAb, monoclonal antibody; NHS, N-hydroxysuccinimide; PBS, phosphate buffer saline; R, SPR response Ž . Ž . at time t RU ; R , equilibrium response RU ; RI, bulk refraceq Ž .
Ž . tive index RU ; R , maximum response RU ; R , total SPR ma x tot Ž . response RU ; RU, resonance units; SDS, sodium dodecylsulfate; SPR, surface plasmon resonance; t , run start time. 
Type of research

Ž
The use of SPR biosensors Fagerstam et al., 1992; Malmqvist and Karlsson, 1997; Homola et al., . 1999 for interaction analysis has made it possible to obtain affinity and kinetic data for a large Ž number of antigen-antibody Brigham-Burke et al., 1992; VanCott et al., 1994; Oddie et al., 1997; . England et al., 1997; Houshmand et al., 1999 , Ž . protein-protein Wu et al., 1995 , protein-peptide Ž . Ž Lessard et al., 1996 and protein-DNA Cheskis . and Freedman, 1996 systems. Other relevant appli-Ž cations are epitope mapping Dubs et al., 1992;  . Saunal and Van Regenmortel, 1995 or selective ( ) concentration analysis of bioactive molecules in Ž . complex samples Richalet-Secordel et al., 1997 . The majority of the direct single-step SPR analyses Ž reported in the literature Altschuh et al., 1992; Wu et al., 1995; Lessard et al., 1996; Brigham-Burke et al., 1992; Lemmon et al., 1994; Tamamura et al., . 1996; Chao et al., 1996; England et al., 1997 involve analytes weighing above 5 kDa. Since the SPR response is directly related to changes in mass on the sensing surface, there is an experimental limitation for direct SPR detection of small analytes, which led to a golden rule in SPR: immobilize the smaller binding partner. A clear example of this rule can be found, for instance, in antigen-antibody interaction studies where antigens are immobilized on the sensor surface and the larger antibodies are used as analytes Ž . Altschuh et al., 1992; Zeder-Lutz et al., 1997 . When this rule is not suitable for the purposes in view, alternative SPR approaches are employed, such Ž as multistep sandwich Cheskis and Freedman, 1996; Huyer et al., 1995; Shen et al., 1996; Lookene et al., . Ž 1996 or indirect competitive Lasonder et al., 1994 Lasonder et al., , 1996 Karlsson, 1994; Zeder-Lutz et al., 1995; Nieba . et al., 1996 analysis. However, in antigen-antibody interaction studies, the general rule is that a high Ž number of potential antigens e.g., peptides with key . residue substitutions are to be screened against a small set of specific antibodies. Thus, antibody immobilization has clear practical benefits over peptide immobilization. Comparison between different peptide antigens is meaningful only if they are analyzed Ž under exactly the same conditions e.g., all injected . over the same antibody surface . Moreover, large Ž . analytes e.g., antibodies are more prone to generate steric hindrance and mass-transport artifacts that affect true kinetic data.
The protocol that we present here is suited for Ž . direct single-step surface plasmon resonance SPR analysis of small ligand-large receptor interactions, Ž where small peptides are used as analytes injected . in the buffer continuous flow and monoclonal anti-Ž . bodies mAb are immobilized on the SPR sensor chip surface. The protocol has been optimized and validated using foot-and-mouth disease virus Ž . FMDV peptides and anti-FMDV neutralizing mAb as the binding partners, as described elsewhere Ž . Gomes et al., 2000a Gomes et al., ,b, 2001a .
Time required
Full kinetic analysis of a peptide-antibody interaction
For routine analyses on a previously prepared sensor surface, 2-3 h will suffice. Considering also ligand immobilization and instrument maintenance procedures, 4-5 h will be required. 
Immobilization of the
Solutions for surface regeneration
The regeneration procedures corresponding to the assays described in the present protocol may, in principle, be carried out using either 50 mM HCl or 10 mM NaOH. The most common regenerating agents are: 
Monoclonal antibodies
Purified mAbs in PBS can be used as stock solutions for subsequent dilution in the immobilization buffer. Generally, mAb stock solutions corre-Ž . Ž . spond to ca. 20 mg antibody rml PBS and are diluted to ca. 5 mgrml in the chosen immobilization buffer.
Immobilization buffers
Preconcentration assays are performed in order to establish which is the best immobilization buffer. Electrostatic preconcentration is best achieved at low ionic strength. A 10-mM sodium acetate buffer with pH s 5.5 is generally adequate for mAb amine coupling immobilization on a CM5 sensor chip. The most common immobilization buffers for sensor chip CM5 are: . 5 mM sodium maleate pH s 5.5-6.0
Peptides
Peptide 2.5 mM stock solutions in water or 100 mM acetic acid can be prepared for 1000-fold and subsequent serial dilutions in the SPR running buffer Ž . HBS . Thus, peptide solutions injected on the biosensor typically range from 2500 to 20 nM in HBS.
Detailed procedure
Preparing the system
System preparation and routine maintenance will not be described in detail since they are presented in the instrumentation manuals. These procedures are almost entirely automated and computer-controlled through interactive software in an icon-based windows environment.
Ž . i Dock the new sensor chip, replace the HBS running buffer bottle by a fresh one and prime the system. Ž .
ii Normalize the probe signal according to the manufacturer's instructions.
Preconcentration assays
Ž .
iii Prepare different mAb solutions to test for the best immobilizing conditions. Different mAb concen-Ž . trations e.g., 5, 10 and 50 mgrml and immobiliza-Ž tion buffers e.g., 10 mM formate, pH 4.5; 10 mM ( ). acetate, pH 5.0; 10 mM acetate, pH 5.5 should be considered.
Ž . iv Select one out of the four independent CM5 sensor chip flow cells and set the running buffer flow rate to 5 mlrmin.
Ž . v Inject sequentially 25 ml of each one of the Ž . Ž different mAb solutions prepared in iii 5-min in-. Ž . jections , with short 1-min pulses of a 1-M ethanol-Ž . amine hydrochloride solution pH s 8.5 between each injection. Ž . vi Examine carefully which combination of mAb concentrationrimmobilization buffer pH is most suitable for efficient ligand electrostatic preconcentration on the sensor chip surface. This corresponds to the lowest ligand concentration and to the highest pH giving maximum response. Immobilization conditions leading to extremely high mAb attachment Ž . rates steep ascent should be avoided.
mAb immobilization by coÕalent amine coupling
Once immobilization conditions are chosen, the mAb can be covalently bound to the sensor chip surface. The amine coupling procedure involves chemical activation of the CM5 surface carboxyl groups and subsequent covalent binding to the mAb primary amino groups.
Ž . vii Prepare the activating mixture by mixing 35 ml of 0.05 M NHS in water with 35 ml of 0.2 M Ž EDC in water the NHS and EDC solutions must be kept separately below 0 8C and should be mixed . immediately before usage .
Ž .
viii Select the flow cell and set the running buffer flow rate to 5 mlrmin.
Ž . Ž . ix Inject 35 ml 7 min of the activating mixture Ža response will be observed due to a change in the . refractive index .
Ž . Ž x Immobilize the ligand by injecting 35 ml 7 . min of the mAb solution chosen in the preconcentration assays, inspecting carefully the slope of the response ascent and the maximum level reached.
Ž . xi Block the nonreacted surface active sites by Ž . injecting 35 ml 7 min of 1 M ethanolamine hydrochloride adjusted to pH 8.5. This will also serve to break remaining ligand-surface electrostatic bonds.
Ž . xii Measure the amount of immobilized ligand Ž . by subtracting the initial AemptyB flow cell from Ž the final baseline level 1000 resonance units-RU 2 .
-correspond to a 1-ngrmm ligand surface density . When performing kinetic analyses, the ligand density should be as low as possible, provided signal-to-noise ratios are adequate. Direct detection of small peptide Ž . antigens ca. 1.5 kDa binding to immobilized mAbs Ž . ca. 150 kDa on a Biacore 1000 generally requires immobilization responses of about 1800 RU.
Ž . xiii Test the regeneration conditions of the surface: this is done by repeated cycles of analyte Ž injection e.g, 25 ml of a 600-nM solution of the . antigenic peptide specific for the immobilized mAb Ž . followed by a short pulse 1-3 min of a regenerat-Ž ing solution the most common ones are mentioned . in Section 3.3 . A suitable regenerating agent provides full recovery of the baseline level at the end of Ž each cycle while preserving ligand activity checked by the constancy of analyte binding level in repeated . cycles .
Binding kinetics assays
Ž .
xiv Dock the sensor chip containing the immobilized mAb, replace the HBS bottle by a new one, prime the system and normalize the probe signal according to the manufacturer's instructions.
Ž . xv Prepare the peptide solutions to be injected. Six or seven different analyte concentrations, e.g., a dilution series ranging from 2500 to 20 nM in HBS, Ž . will suffice. One blank sample buffer only and a Ž . negative control analyte e.g., scrambled peptide should be included in the analyses. The regeneration solution should also be prepared.
Ž . xvi Set the running buffer flow rate to 60 mlrmin on the flow cell containing the immobilized Ž ligand for kinetic analyses, buffer flow rates must be higher than 30 mlrmin to avoid diffusion-con-. trolled kinetics .
Ž . xvii Program the injection cycle: use the Akinject mode,B which minimizes sample dispersion and provides user-defined dissociation times in running Ž buffer. Needle-cleaning operations Apredip needleB before analyte injection and Aextra clean-upB after . regeneration should be also included in each cycle to avoid carry-over. Each cycle comprises two main steps:
Ž . a AkinjectB 90 ml 1.5 min of sample solution Ž . followed by 4 min 240 s dissociation in running buffer.
Ž . b inject 60 ml 1 min of the regenerating solution.
Ž . xviii Program the peptide binding assays: each peptide should be analyzed at least at six different Ž concentrations each corresponding to one injection Ž .. cycle as described in xvii . Each measurement should be run at least in triplicate and injections should preferably follow a random order. Flush the system whenever a new peptide is to be screened and prime the system once a day.
Data processing and analysis
Data processing is done by means of the BIAEvaluatione software available from Biosensor. Ex-Ž . perimental curves i.e., sensorgrams corresponding Ž . to the same analyte at different concentrations are simultaneously processed. The software includes several kinetic models and nonlinear least squares methods to optimize parameter values. Simple kinetic models perfectly described by integrated rate equations use analytical integration, while more Ž complex ones e.g., involving mass transport limitations, ligand or analyte heterogeneity, conformational changes, analyte multivalency or ligand coop-. erativity use numerical integration.
Ž . xix Open a new BIAevaluation file and, from there, access all the experimental curves corresponding to a given peptide-mAb system analyzed under Ž identical conditions except for varying peptide con-. centration . Also from the same file, open the experimental curves corresponding to the blank run and to the negative-control peptide injections.
Ž . Ž . xx Adjust the time scale abscissa so that t s 0 Ž . injection start is the same for all curves, and the Ž . baseline level ordinate, before injection start so that it equals 0 RU in all sensorgrams.
Ž . xxi Delete the useless parts of the sensorgrams Ž . e.g., the regeneration pulses , after which subtract Ž . the blank run buffer only curve to all the others Žthis will eliminate buffer response and instrumental . drifts or artifacts .
Ž . xxii Subtract from each peptide concentration curve the one from the scrambled peptide, to eliminate nonspecific binding.
Ž . xxiii Fit the set of binding curves by global curve fitting to those kinetic models compatible with your system. Judge which one gives the best fit and Ž the most reliable parameters a 1:1 Langmuirian behavior-pseudo-first order reaction-should be expected for the interaction between each antigen molecule and each one of the Fabs on the immobi-. lized mAb .
The fitting models are based on AblindB mathematical tools and the Abest fitB depends on the ability of the fitting algorithm to converge for the true minimum and on the number of parameters that can be varied in the model, i.e., the complexity of Ž the model O' Shannessy et al., 1993; Morton et al., . 1995 . Therefore, caution must be taken when judging the Abest fitB from a purely mathematical point of view. In general, the best choice is the simplest model of those giving reasonably good fits.
Ž . xxiv Once the Abest fitB is chosen, a further detailed evaluation should be performed in order to Ž establish data consistency Schuck and Minton, . 1996 . Different zones of the experimental curves should be used for fitting purposes. Local fittings Ž . each sensorgram separately should be done and compared with globally fitted data. When applicable, Ž analytical integration methods separate fitting of . association and dissociation phases should be tested and compared with numerical integration methods. Ž This means that, for a 1:1 interaction pseudo-first . order kinetics , data should be fitted as follows: If kinetic parameters are consistent throughout all these fits, the kinetic model chosen is most probably correct and interaction data are meaningful.
Results
In this section, examples of the expected results will be presented for each one of the main stages of the analysis protocols. Fig. 1 illustrates the results of three sequential preconcentration assays. Using ca. 1700 RU as a reasonable immobilization level for the direct kinetic assay of small peptide binding to an antibody sur-Ž face, situation A 5 mgrml mAb in 10 mM acetate . buffer, pH 5.5 is clearly the most satisfactory. In B Ž . 5 mgrml mAb in 10 mM formate buffer, pH 4.5 , mAb response increases rather slowly and the final Ž mAb level is insufficient. In contrast, situation C 50 . mgrml mAb in 10 mM acetate buffer, pH 5.5 corresponds to a fast mAb uptake by the surface resulting in a too high mAb final density.
Preconcentration assays
Antibody coÕalent immobilization
A standard ligand covalent immobilization monitored by SPR is depicted in Fig. 2 . In a first stage Ž . 1 , the EDCrNHS activating mixture is injected with the consequent increase in the SPR signal due to a change in the bulk refractive index. The mAb Ž . solution is then injected and the binding event 2 can be followed in real time. Once the adequate binding level is reached, the remaining active carboxyl-NHS esters are blocked with ethanolamine Ž . hydrochloride 3 , causing a significant change in the bulk refractive index. The biospecific mAb surface is Ž . then ready to be used 4 .
Binding assays
The binding assays consist of sequential peptide injection plus regeneration cycles. Fig. 3A shows the three main stages observed when monitoring the Ž . . Ž . and dissociation in running buffer . 3 Ligand surface regeneration.
Each cycle corresponds to a new sample, so that all blanks, controls, different peptide concentrations Ž and assay repeats are covered. When a full set i.e., . all concentrations of a given peptide of injection cycles is finished, the corresponding sensorgrams can be transformed in order to eliminate irrelevant Ž . regions e.g., regeneration pulses and to normalize the time and response axes. This results in the super-Ž . position of several sensorgrams Fig. 3B , ready to be processed by the curve fitting software. Table 1 Kinetic and affinity data from the SPR analysis of the peptide-immobilized antibody interaction illustrated in Fig. 4 y1 y1 y1 y1 
Data processing and eÕaluation
Fig . 4 depicts the most important stages in data processing and evaluation. In A, sensorgrams corresponding to a nonspecific peptide injected on a mAb surface are shown. The sensorgrams are square-wave shaped due to a mere refractive index jump, which is confirmed by the fact that no peptide is bound to the mAb at the beginning of the dissociation phase. In B, sensorgrams correspond to a specific interaction between an injected peptide and the immobilized mAb. This same interaction is depicted in C, after being corrected by subtraction of the sensorgrams corre-Ž sponding to the nonspecific peptide analogue shown . in A . Sensorgrams in C were globally fitted to a 1:1 interaction model, with calculated curves totally coincident with the experimental ones and residuals Ž . randomly distributed around zero Fig. 4D , corresponding to a chi-squared lower than 1. The kinetic parameters obtained are shown in Table 1 . These sensorgrams were also fitted locally to the same Ž . kinetic model Table 1 .
Further local fitting was performed using the sep-Ž . arate k rk model Table 1 
Discussion
Trouble-shooting
Immobilization is not satisfactory
The immobilization level depends on several factors, such as ligand concentration, pH, ionic strength, Ž . activation time EDCrNHS mixture and injection Ž . time ligand . Generally, lower ligand binding levels can be reached by decreasing ligand concentration, pH, activation and contact times or by increasing ionic strength. Conversely, higher concentrations and activation or contact times, as well as lower ionic strength, contribute to increase ligand immobilization levels.
Baseline responses increase oÕer repeated cycles
The regeneration step is not efficient and bound analyte is not fully washed off after each binding cycle. Regenerating agents must be tested and a Ž . cocktail approach Andersson et al., 1999a ,b may be required.
Binding leÕels decrease oÕer repeated cycles
There is loss of ligand activity, either due to ligand inactivation under the analysis conditions em-
. ployed inadequate buffers, regeneration agents, etc. Ž or to blockage of ligand binding sites extremely strong analyte-ligand interactions, ineffective regen-. eration steps . Different immobilization methodologies or regeneration conditions may solve the problem.
Expected binding is not obserÕed
If analyte or ligand degradation prior to usage in the biosensor experiments can be discarded, then ligand inactivation during immobilization must be suspected. Alternative immobilization strategies Ž should be tested e.g., thiol coupling, binding of biotinylated ligand to a streptavidin surface, immobilization of mAb to an anti-mouse Fc antibody sur-. face .
Data do not fit to the expected kinetic model
Ž . Generally, antigen-antibody Fab interactions display a Langmuirian behavior on the biosensor. Deviations from pseudo-first order kinetics, one of the most difficult problems to solve in biosensor Ž analysis Morton et al., 1995; O'Shannessy and Win-. zor, 1996; Hall et al., 1996 , can arise from several factors. The consideration is that, when kinetic studies are to be carried out, mass transport effects must be minimized. This can be achieved by decreasing Ž the ligand immobilization level e.g., to the minimum amount giving a satisfactory signal-to-noise . Ž ratio , or by increasing buffer flow rate always higher than 30 mlrmin and as high as sample con-. sumption, thus, permits , or by increasing analyte Ž concentration as long as surface binding capacity is . not saturated . Mass transport influence can be tested by analyzing the effect of different buffer flow rates Ž on analyte initial binding rates curve slopes at the . initial stage of the association step . Another precaution aimed to eliminate mass transport effects in complex dissociation consists in using a ligand solution instead of buffer during the dissociation phase.
Other common sources of deviation are ligand or analyte heterogeneity. The first is mainly due to random immobilization procedures and can be minimized by lowering binding levels or using oriented methodologies such as streptavidin-biotin or antiFc-Fc indirect immobilization. Analyte heterogeneity can be reduced through additional sample purification steps.
The sources of deviation most difficult to deal with are those intrinsic to the binding partners or phenomena, such as analyte multivalency, avidity, or Ž complex binding mechanisms e.g., involving con-. formational changes . When these effects are present, the only way to take them into account is to use the more complex fitting models included in the evaluation software, although it may be difficult to judge whether a good fit corresponds to the real Ž . binding mechanism Schuck, 1997 .
Buffer and sample refractiÕe indices mismatch
Whenever sample and running buffers are differ-Ž . ent, nonspecific bulk refractive index RI jumps Ž take place square-wave shaped signals superimpose . to the binding curves . Although such bulk RI response may be eliminated by subtraction of a blank run, useful information from stages immediately after the injection pulse may be lost. Thus, sample buffer should resemble the running buffer as close as possible.
Nonspecific binding
Nonspecific binding may become a problem when using unpurified samples, such as cell lysates, hybridomas, etc. Anyway, nonspecific binding should Ž . be checked by one of the following ways. 1 Sample injection on both the specific cell and a reference cell. This reference cell must be prepared as simi-Ž larly as possible to the specific one e.g., same coupling chemistry to immobilize a similar amount . Ž . of inactivated ligand . 2 Another approach, perhaps more appropriate, consists of injection of a non-Ž specific analyte e.g., peptide with randomized se-. quence .
BIAcore 2000 and 3000 instruments allow to monitor interactions on the four different sensor chip cells with a single sample injection, thus, providing simultaneous analysis of analyte binding to three different receptors plus a reference cell at minimal sample costs.
AlternatiÕe procedures
The direct single-step approach presented here is the simplest way to study biospecific interactions and is advisable for kinetic studies. However, sometimes the systems under study cannot be suitably ( )characterized by this method and alternative approaches may be required. Standard alternative SPR methodologies include the following:
Direct multistep approach
This consists of immobilization of a ligand followed by binding of a specific analyte followed by Ž injection of a second binding partner that binds the . first analyte is injected. Each binding stage is monitored in real-time and this approach is often em-Ž . ployed for binding site analysis Dubs et al., 1992 Ž and analyte response enhancement Van Regenmor-. tel et al., 1994 .
Indirect surface-competition assay
This is used in kinetic studies of low molecular weight analytes and consists of injecting a specific high molecular weight analyte followed by competition experiments using the small target analyte as Ž . competitor Karlsson, 1994 . This requires a macromolecule possessing the same binding specificity of Ž the small target analytes e.g., a viral protein compet-. ing with a small peptide antigen .
Solution affinity experiments
These are widely employed for small analyte detection, with the disadvantage that they do not provide kinetic information. This approach resembles a competition ELISA experiment in the sense that a Ž . suitable analyte e.g., native peptide antigen is immobilized on the sensor surface and preincubated Ž mixtures of analyte-receptor e.g., other peptide . antigensq specific antibody are injected. Incubating variable analyte concentrations with a constant receptor concentration allows to build inhibition curves Ži.e., free receptor concentration vs. analyte concen-. tration , from which binding constants can be with-Ž . drawn Nieba et al., 1996; Gomes et al., 2001b,c,d . Ž . ix Prepare 0.2 M EDC and 0.05 M NHS solu-Ž tions also available from Biosensor; these solutions, once prepared, should be divided into 100-ml aliquots . and stored below 0 8C .
Essential references
x Mix 50 ml of the EDC solution with an equal volume of the NHS solution, and immediately inject 35 ml of this mixture at 5 mlrmin, to activate the sensor surface. Solutions can be mixed using the automatic sampling unit of the instrument.
Ž . xi Inject 35 ml of the mAb solution chosen in Ž . viii . Binding levels can be controlled at this stage by either interrupting the injection or appending extra injections of the mAb solution.
Ž . xii Block the remaining active sites on the surface with a 30-ml injection of 1 M ethanolamine hydrochloride, pH 8.5.
Ž . xiii Prepare solutions for testing regeneration conditions, starting with the most commonly used for mAb-peptide binding assays: v 10 mM HCl; v 10 mM NaOH.
Ž .
xiv Select a peptide expected to bind signifi-Ž cantly to the mAb e.g., the native antigenic se-. quence and dilute the stock solution to 600 nM in HBS.
Ž . xv Test the regenerating agents by alternating injections of 15 ml of peptide and 10 ml of regenerating solutions. If common regenerating agents are not adequate, try other possibilities until an agent capable of restoring the baseline level while keeping mAb binding activity is found. Then, proceed to the binding kinetics analyses as described below.
Ž 
